



December 9, 2004

U.S. Nuclear Regulatory Commission
Region 1
475 Allendale Road
King of Prussia, PA 19406

Q-2

Attn: Mr. Sattar Lodhi
Division of Nuclear Materials Safety

Fax: 610-337-5269

RE: License No. 07-28386-01 Amendment Request
Control No. 136077

03031174

Dear Mr. Lodhi:

Referencing our conversation on December 9, 2004 and QTT's license amendment request dated December 7, 2004 for an increase in the possession limit of I-131, we are providing some additional information.

The increase in activity is to accommodate a job being performed at a remote location. The job is expected to take several days and will consist of several injections into a closed system. Subsequently, the 2 Ci being requested will not be injected all at once. Normally we would use a shorter half-life isotope, but due to the remote location and the potential for job delays we are choosing to use I-131.

Pursuant to Section 5.0 (Bioassay Program) of our Administrative Procedures, each employee handling the I-131 in an unsealed condition will be required to have a baseline and post-job bioassay. The bioassay will be analyzed by an independent laboratory. Additionally, the exposed employees will have a post-job thyroid uptake monitoring performed at a nuclear medicine facility, such as a hospital.

Should you have any questions, I can be reached at 281-471-8715 or 281-386-6385. Your assistance in the matter is greatly appreciated.

Best regards,

A handwritten signature in cursive script, appearing to read 'Norman Lanier'.

Norman P. Lanier
Corporate Radiation Safety Officer

136077

NMSS/RGNI MATERIALS-002